|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||38.72 - 38.92|
|52 Week Range||25.80 - 40.71|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||17.41|
|Forward Dividend & Yield||0.26 (0.67%)|
|Ex-Dividend Date||Mar 27, 2020|
|1y Target Est||N/A|
Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field
MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.
Although the plan appears to have met opposition from some advisers to U.S. President Donald Trump and there is no clarity on when and where the deal will be signed, investors have so far bet that a deal will come through in the end. "If you think corporate earnings will recover from here, you can expect further rise in share prices. Investors are now starting to expect such a scenario, which you can tell from the fact that cyclicals such as financials and energy shares are doing well," said Takuya Hozumi, global investment strategist at Mitsubishi UFJ Morgan Stanley.